Penumbra, Inc.

PEN Healthcare Medical Devices

Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.

Revenue
+15.6%
EPS
−8.29%
Free cash flow
−37.2%
Total debt
−10.3%

Quarter to September 2026, against a year earlier

319.96 1.15 −0.36%
Market cap
$12.7B
P/E
80.3×
Fwd P/E
68.7×
Dividend yield
—
F-score
8/9
Altman Z
20.17
Beneish M
−2.48
Dividend safety
n/a

Penumbra, Inc. (PEN) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by products and services, and margins
Thrombectomy 948 67.53%
Embolization and Other 456 32.47%
Gross margin 67.14%
Operating margin 13.48%
Pre-tax margin 14.61%

Revenue by product or service $m

Line FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013
Thrombectomy 948 815 677 511 438 — — — — — — — —
Embolization and Other 456 379 381 336 310 — — — — — — — —
Neuro — — — — — 293 332 294 232 186 141 106 81
Peripheral Vascular — — — — — 268 216 151 101 78 45 19 8
Revenue 1,404 1,195 1,059 847 748 560 547 445 334 263 186 126 89

Revenue by region $m

Line FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013
United States 1,092 902 757 592 528 400 355 291 219 176 127 83 58
International 312 293 301 255 220 160 192 154 81 57 40 28 18
Japan — — — — — — — — 34 30 19 15 13
Revenue 1,404 1,195 1,059 847 748 560 547 445 334 263 186 126 89

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.